Prime Medicine Announces Financial Results for Q3 2025 and Shares Business Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy PRME?
Source: Newsfilter
Preclinical Data Presentation: Prime Medicine will present new preclinical data for PM577 targeting Wilson's Disease at the AASLD meeting, with plans to file an IND and/or CTA in H1 2026 and initial clinical data expected in 2027.
Development Candidate for AATD: The company has nominated PM647 as the development candidate for Alpha-1 Antitrypsin Deficiency, aiming to file an IND and/or CTA by mid-2026, also with initial clinical data anticipated in 2027.
Leadership Appointment: Matthew Hawryluk, Ph.D., M.B.A., has been appointed as Chief Business Officer to enhance Prime Medicine's business development and strategic collaborations.
Financial Overview: For Q3 2025, Prime Medicine reported a net loss of $50.6 million, with cash reserves of $213.3 million expected to fund operations into 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRME
Wall Street analysts forecast PRME stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.380
Low
4.25
Averages
6.06
High
9.00
Current: 3.380
Low
4.25
Averages
6.06
High
9.00
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
Prime Medicine Focuses on Liver Franchise with $191.4M Cash Runway
- Financial Overview: Prime Medicine ended fiscal year 2025 with $191.4 million in cash and equivalents, ensuring financial stability through 2027 despite a net loss of $201.1 million, highlighting challenges in financial management.
- Stable R&D Spending: The company maintained R&D expenses at $160.6 million, indicating a commitment to advancing high-priority clinical milestones while optimizing its workforce amidst financial pressures, particularly in liver-related projects.
- Clinical Progress and Regulatory Path: Prime Medicine plans to submit IND or CTA for Wilson Disease in H1 2026 and for AATD in mid-2026, with initial clinical data for both expected in 2027, showcasing its strategic focus on liver disease treatments.
- FDA Accelerated Approval: The company is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate PM359, based on positive Phase 1/2 data published in the New England Journal of Medicine, which could make PM359 the first Prime Edited therapy available to patients.
See More
Prime Medicine Reports FY 2023 Financial Results
- Financial Performance: Prime Medicine reported a FY GAAP EPS of -$1.35, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Details: The company generated revenue of $4.63 million, which, while showing some growth, fell short of market expectations, potentially putting pressure on the stock price.
- Market Reaction: Following the Q4 updates, Prime Medicine's stock slipped, reflecting investor concerns over financial performance that could impact future fundraising capabilities.
- Investment Rating: Despite these challenges, analysts maintain a 'Buy' rating on Prime Medicine, suggesting optimism regarding its solidified catalysts for Wilson's disease and other potential developments.
See More
Prime Medicine Reports Q4 2025 Results and Future Milestones
- Financial Performance: Prime Medicine reported a Q4 2025 net loss of $0.24 per share with revenue of $838K, both falling short of market expectations of $0.26 and $2.1M, indicating challenges in revenue growth.
- Cash Flow Status: As of December 31, Prime's total cash, cash equivalents, investments, and restricted cash reached $191.4M, reflecting a ~6% year-over-year decline, although the liquidity level is sufficient to fund operations and capital expenses through 2027, future funding needs remain a concern.
- FDA Accelerated Approval Plans: The company plans to submit a Biologics License Application for its gene editing therapy PM359 targeting chronic granulomatous disease to the FDA, with existing clinical data expected to support accelerated approval, which could significantly enhance its market position in the rare disease sector.
- Clinical Research Progress: For liver-focused programs targeting Wilson's disease and Alpha-1 Antitrypsin Deficiency, Prime expects to apply for an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) in H1 2026 and mid-2026, respectively, with topline data from both programs scheduled for release next year, further advancing the company's research agenda.
See More
Prime Medicine to Participate in Three Major Conferences
- Conference Schedule: Prime Medicine will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its latest advancements in gene editing technology during a fireside chat.
- One-on-One Meetings: Company management will host one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami Beach, aiming to engage deeply with investors and explore potential financing opportunities.
- Technology Showcase: At the Citizens Life Sciences Conference on March 11, 2026, Prime Medicine will conduct another fireside chat to elaborate on its unique Prime Editing platform and its potential applications in gene therapy.
- Live Webcasts: All fireside chats will be available via live webcasts on the company's website, with replays accessible for 90 days post-event, ensuring investors and the public can stay informed about key developments.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
Prime Medicine Focuses on Liver Franchise with $191.4M Cash Runway
- Financial Overview: Prime Medicine ended fiscal year 2025 with $191.4 million in cash and equivalents, ensuring financial stability through 2027 despite a net loss of $201.1 million, highlighting challenges in financial management.
- Stable R&D Spending: The company maintained R&D expenses at $160.6 million, indicating a commitment to advancing high-priority clinical milestones while optimizing its workforce amidst financial pressures, particularly in liver-related projects.
- Clinical Progress and Regulatory Path: Prime Medicine plans to submit IND or CTA for Wilson Disease in H1 2026 and for AATD in mid-2026, with initial clinical data for both expected in 2027, showcasing its strategic focus on liver disease treatments.
- FDA Accelerated Approval: The company is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate PM359, based on positive Phase 1/2 data published in the New England Journal of Medicine, which could make PM359 the first Prime Edited therapy available to patients.
See More
Prime Medicine Reports FY 2023 Financial Results
- Financial Performance: Prime Medicine reported a FY GAAP EPS of -$1.35, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Details: The company generated revenue of $4.63 million, which, while showing some growth, fell short of market expectations, potentially putting pressure on the stock price.
- Market Reaction: Following the Q4 updates, Prime Medicine's stock slipped, reflecting investor concerns over financial performance that could impact future fundraising capabilities.
- Investment Rating: Despite these challenges, analysts maintain a 'Buy' rating on Prime Medicine, suggesting optimism regarding its solidified catalysts for Wilson's disease and other potential developments.
See More
Prime Medicine Reports Q4 2025 Results and Future Milestones
- Financial Performance: Prime Medicine reported a Q4 2025 net loss of $0.24 per share with revenue of $838K, both falling short of market expectations of $0.26 and $2.1M, indicating challenges in revenue growth.
- Cash Flow Status: As of December 31, Prime's total cash, cash equivalents, investments, and restricted cash reached $191.4M, reflecting a ~6% year-over-year decline, although the liquidity level is sufficient to fund operations and capital expenses through 2027, future funding needs remain a concern.
- FDA Accelerated Approval Plans: The company plans to submit a Biologics License Application for its gene editing therapy PM359 targeting chronic granulomatous disease to the FDA, with existing clinical data expected to support accelerated approval, which could significantly enhance its market position in the rare disease sector.
- Clinical Research Progress: For liver-focused programs targeting Wilson's disease and Alpha-1 Antitrypsin Deficiency, Prime expects to apply for an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) in H1 2026 and mid-2026, respectively, with topline data from both programs scheduled for release next year, further advancing the company's research agenda.
See More
Prime Medicine to Participate in Three Major Conferences
- Conference Schedule: Prime Medicine will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its latest advancements in gene editing technology during a fireside chat.
- One-on-One Meetings: Company management will host one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami Beach, aiming to engage deeply with investors and explore potential financing opportunities.
- Technology Showcase: At the Citizens Life Sciences Conference on March 11, 2026, Prime Medicine will conduct another fireside chat to elaborate on its unique Prime Editing platform and its potential applications in gene therapy.
- Live Webcasts: All fireside chats will be available via live webcasts on the company's website, with replays accessible for 90 days post-event, ensuring investors and the public can stay informed about key developments.
See More
